Clinical Treatment of Gastroenterology in Patients with Chronic Atrophic Gastritis

Objective: To observe the clinical manifestations of selected patients with chronic atrophic gastritis, and to collect data to explore the clinical treatment effect of tepredone in the Department of Gastroenterology in patients with chronic atrophic gastritis. Methods: A total of 160 patients with chronic atrophic gastritis were selected among the patients admitted to the hospital for treatment from August 2019 to August 2022, and a total of 160 patients were selected as the experimental subjects of this clinical treatment study of gastroenterology in patients with chronic atrophic gastritis. 160 patients with chronic atrophic gastritis will be randomly divided into two groups, 80 cases in each group, to ensure that the difference between the study group and the control group is statistically significant to ensure the availability of experimental data. In the experiment, 80 patients with chronic atrophic gastritis in the control group received triple therapy with conventional treatment in gastroenterology, while 80 patients with chronic atrophic gastritis in the study group added tipredone therapy to the triple therapy of conventional treatment in gastroenterology. A two-week treatment cycle compares the effects of treatment between the study and control groups, collects data and draws corresponding conclusions. Results: After treatment, the total effective rate of treatment in the study group was 97.5%, which was higher than that in the control group, and the difference was statistically significant. Conclusion: In patients with chronic atrophic gastritis, on the basis of conventional treatment in gastroenterology, the addition of tepredone therapy has positive significance for the treatment effect of chronic atrophic gastritis, and can be promoted